Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of life sciences executive Robert Johnson as Chief Executive Officer. Johnson joins ...
Decades of research on genetic mutations have had one overriding goal: to understand how specific mutations interfere with physiological processes and promote disease. Adrestia Therapeutics, a ...
CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H ...
GlaxoSmithKline, alongside Ahren Innovation Capital, will co-lead series A investment in UK-based biotech company Adrestia Therapeutics. Adrestia uses molecular biology to develop precision medicines ...
MARTINSRIED, Germany and Munich, Germany, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH (“Proteros”) today announced that it has initiated a multi-target drug discovery partnership ...
GlaxoSmithKline plc and Ahren Innovation Capital (Ahren) announced they will co-lead a Series A investment in Adrestia Therapeutics (Adrestia), a UK-based biotechnology company using cutting edge ...
Genetic medicine executive brings deep sector expertise to synthetic rescue leader Pioneering platform charting world-first druggable target opportunities for diseases with a genetic component ...
Will brings a strong track record of creating value through company-building, deep relationships with capital markets and rare disease drug development and commercialization experience Other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results